Bonness Enterprises’s Merck MRK Stock Holding History

Bonness Enterprises’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.93M	Hold	69,500	–	–	2.88%	11
2026 Q1	$8.36M	Hold	69,500	–	–	3.06%	8
2025 Q4	$7.32M	Hold	69,500	–	–	2.52%	10
2025 Q3	$5.83M	Hold	69,500	–	–	1.91%	10
2025 Q2	$5.5M	Hold	69,500	–	–	1.8%	11
2025 Q1	$6.24M	Hold	69,500	–	–	2.04%	8
2024 Q4	$6.91M	Hold	69,500	–	–	2.43%	5
2024 Q3	$7.89M	Hold	69,500	–	–	2.62%	5
2024 Q2	$8.6M	Hold	69,500	–	–	3.15%	5
2024 Q1	$9.17M	Hold	69,500	–	–	3.31%	5
2023 Q4	$7.58M	Hold	69,500	–	–	3.17%	5
2023 Q3	$7.16M	Hold	69,500	–	–	3.28%	5
2023 Q2	$8.02M	Hold	69,500	–	–	3.61%	5
2023 Q1	$7.39M	Hold	69,500	–	–	3.29%	5
2022 Q4	$7.71M	Hold	69,500	–	–	3.63%	4
2022 Q3	$5.99M	Hold	69,500	–	–	3.18%	6
2022 Q2	$6.34M	Hold	69,500	–	–	3.17%	6
2022 Q1	$5.7M	Hold	69,500	–	–	2.62%	8
2021 Q4	$5.33M	Hold	69,500	–	–	2.46%	8
2021 Q3	$5.22M	Hold	69,500	–	–	2.66%	7
2021 Q2	$5.41M	Sell	69,500 -3,336	-5%	-$248K	2.72%	7
2021 Q1	$5.36M	Buy	72,836 +23,161	+47%	+$1.71M	2.87%	7
2020 Q4	$3.88M	Hold	49,675	–	–	2.17%	10
2020 Q3	$3.93M	Hold	49,675	–	–	2.31%	9
2020 Q2	$3.67M	Hold	49,675	–	–	2.35%	10
2020 Q1	$3.65M	Hold	49,675	–	–	2.64%	6
2019 Q4	$4.31M	Hold	49,675	–	–	2.71%	6
2019 Q3	$3.99M	Hold	49,675	–	–	2.56%	8
2019 Q2	$3.98M	Hold	49,675	–	–	2.48%	9
2019 Q1	$3.94M	Hold	49,675	–	–	2.56%	9
2018 Q4	$3.62M	Hold	49,675	–	–	2.72%	8
2018 Q3	$3.36M	Hold	49,675	–	–	2.2%	12
2018 Q2	$2.88M	Hold	49,675	–	–	2.03%	14
2018 Q1	$2.58M	Sell	49,675 -2,096	-4%	-$113K	1.8%	17
2017 Q4	$2.78M	Hold	51,771	–	–	1.89%	17
2017 Q3	$3.16M	Hold	51,771	–	–	2.26%	12
2017 Q2	$3.17M	Hold	51,771	–	–	2.42%	9
2017 Q1	$3.14M	Hold	51,771	–	–	2.51%	10
2016 Q4	$2.91M	Sell	51,771 -3,668	-7%	-$215K	2.61%	11
2016 Q3	$3.3M	Hold	55,439	–	–	2.74%	9
2016 Q2	$3.05M	Hold	55,439	–	–	2.56%	11
2016 Q1	$2.8M	Hold	55,439	–	–	2.41%	11
2015 Q4	$2.79M	Hold	55,439	–	–	2.51%	11
2015 Q3	$2.61M	Hold	55,439	–	–	2.49%	11
2015 Q2	$3.01M	Buy	55,439 +314	+0.6%	+$17.6K	2.71%	9
2015 Q1	$3.02M	Hold	55,125	–	–	2.69%	9
2014 Q4	$2.99M	Hold	55,125	–	–	2.58%	10
2014 Q3	$3.12M	Sell	55,125 -524	-0.9%	-$29.4K	2.8%	10
2014 Q2	$3.07M	Sell	55,649 -5,240	-9%	-$286K	2.78%	9
2014 Q1	$3.3M	Hold	60,889	–	–	2.9%	9
2013 Q4	$2.91M	Hold	60,889	–	–	2.57%	10
2013 Q3	$2.77M	Hold	60,889	–	–	2.66%	10
2013 Q2	$2.7M	Buy	+60,889	New	+$2.72M	2.68%	10

Other funds holding MRK

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

ECSS

Eurizon Capital SGR SpA Milan $37.3B AUM

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Bonness Enterprises's MRK Position: Q2 2026 in Review

Bonness Enterprises held its Merck (MRK) position steady in Q2 2026 at 69,500 shares worth $8.93M. The position accounts for 2.88% of the portfolio, ranked #11.

Bonness Enterprises first reported a position in MRK in Q2 2013 and has held it in 53 quarters since. The position peaked at $9.17M in Q1 2024. 1,889 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

Bonness Enterprises held 69,500 shares of Merck worth $8.93M as of Q2 2026.
Bonness Enterprises left its Merck share count unchanged in Q2 2026.
Merck made up 2.88% of Bonness Enterprises's portfolio in Q2 2026, its #11 holding.
Bonness Enterprises first reported a position in Merck in Q2 2013 and has held it in 53 quarters since.
Bonness Enterprises's Merck position peaked at $9.17M in Q1 2024.
1,889 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Bonness Enterprises's 13F filing for Q2 2026, filed 9 Jul 2026.